An Open Label, Multi Centre, Phase II Study to Evaluate the Safety and Efficacy of Coramsine Injection in Patients with Melanoma

Exclusion Criteria1

• Patients with an active infection requiring oral or intravenous antibiotics 2. Patients with significant cardiac or pulmonary disease or evidence of any other significant medical condition, which in the opinion of the principal investigator could impair the ability of the patient to participate in the trial. 3. Patients with recent (< 6 months) peptic ulcerations or upper GI bleeding. 4. Pregnant or lactating women. 5. Reactions to the Solanum species (potatoes, tomatoes, aubergines and capsicum). 6. History of adverse reactions to related compounds. 7. Active brain or other CNS metastases. Stable/controlled brain metastases are permitted following treatment with surgery or radiation therapy. A minimum of 4 weeks must have elapsed since surgical or radiation treatment of brain metastases. 8. Unwilling/unable to have a venous access device inserted. 9. Known seropositive to HIV, Hepatitis B or Hepatitis C 10. Any other active malignancy 11. Patients must not have had any radiotherapy for 3 weeks prior to entering the study, and must be fully recovered from the acute effects of any prior radiotherapy. 12. Patients must not have greater than 2 previous regimens of chemotherapy treatment for Melanoma. Prior treatment with cytokines, vaccines, antiangiogenic agents or signal transduction inhibitors is permitted. 13. Patients must not have had any other tumour treatment medications for 30 days prior to entering the study. 14. Patients must not be actively receiving any other investigational therapy, nor received any experimental agents within the previous 30 days. 15. Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.